MRS efficacy in distinction between benign and malignant lesions

Document Type : Review

Authors

1 Department of Medical physics,faculty of medicine ,Ahvaz jundishapur university of medical sciences , Ahvaz , Iran

2 Associated professor of Medical Physics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

3 Assistant professor of Radiology, Faculty of Para Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

4 Assistant professor of Urology department, School of medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

5 Assistant professor of radiology department, School of medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Abstract

Abstract
Objective: Considering non-invasive, sensitivity and appropriateness of Magnetic Resonance Spectroscopy and its ability to detect prostate lesions in the early stages; this study aimed to review the MRS efficacy to distinguish benign and malignant prostate lesions, systematically.
Materials and Methods: PubMed, Science Direct, Embase, Cochran and Scopus databases were explored using the MRS & prostate, prostate, prostatitis, BPH, and Magnetic Resonance Spectroscopy keywords. The obtained results were screened for the Title and abstract by to authors and the relevant papers were reviewed for further details.
Results: Sensitivity, specificity and accuracy of MRS were 74.03%, 74.27% and 77.26%, respectively, in differentiating benign and malignant prostate lesions. The increase of choline and myoinozytol, reduction of citrate and polyamine, and the ratio of the higher sum of choline and creatine to citrate in malignant lesions are presented as the main markers.
Conclusion: MRS as a non-invasive method has an optimal sensitivity, specificity and accuracy compared with other clinical and pathological methods.
Key words: MRS, prostate, cancer, prostatitis, BPH .

Keywords

References

1-Futterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241(2):449-58.
2-Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate cancer and prostatic diseases. 2012;15(1):45-55.
3-Collins MM, Stafford RS, O'leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. The Journal of urology. 1998;159(4):1224-8.
4-Jacobs MA, Ouwerkerk R, Petrowski K, Macura KJ. Diffusion weighted imaging with ADC mapping and spectroscopy in prostate cancer. Topics in magnetic resonance imaging: TMRI.2008;19(6):261.
5-Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. European urology. 2011;59(1):61-71.
6-Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level≤ 4.0 ng per milliliter. New England Journal of Medicine. 2004;350(22):2239-46.
7-Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. The Journal of urology. 2001;166(3):856-60.
8-Kumar V, Jagannathan NR, Thulkar S, Kumar R. Prebiopsy magnetic resonance spectroscopy and imaging in the diagnosis of prostate cancer. International Journal of Urology. 2012;19(7):602-13.
9-Thörmer G, Otto J, Horn L-C, Garnov N, Do M, Franz T, et al. Non-invasive estimation of prostate cancer aggressiveness using diffusion-weighted MRI and 3D proton MR spectroscopy at 3.0 T. Acta Radiologica. 2015;56(1):121-8.
10-Tahmasebibirgani MJ, Maskani R, Behrooz MA, Zabihzadeh M, Shahbazian H, Fatahiasl J, et al. Simulation of therapeutic electron beam tracking through a non-uniform magnetic field using finite element method. Electronic physician. 2017;9(4):4171.
11-Zabihzadeh M, Pishghadam M, Kazemi K, Nekooi S, Tahmasebi Birgani MJ, Seilanian-Toosi F. Comparison the Accuracy of Fetal Brain Extraction from T2-Half-Fourier Acquisition Single-Shot Turbo Spin-Echo (HASTE) MR Image with T2-True Fast Imaging with Steady State Free Precession (TRUFI) MR Image by Level Set Algorithm. International Journal of Pediatrics.  2017;5(3):4561-7 .
12-Panebianco V, Barchetti F, Musio D, Forte V, Pace A, De Felice F, et al. Metabolic atrophy and 3‐T 1H‐magnetic resonance spectroscopy correlation after radiation therapy for prostate cancer. BJU international. 2014;114(6):852-9.
13-Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology. 1996;198(3):795-805.
14-Wang P, Guo Y-m, Liu M, Qiang Y-q, Guo X-j, Zhang Y-l, et al. A meta-analysis of the accuracy of prostate cancer studies which use magnetic resonance spectroscopy as a diagnostic tool. Korean journal of radiology. 2008;9(5):432-8.
15-Mueller-Lisse UG, Vigneron DB, Hricak H, Swanson MG, Carroll PR, Bessette A, et al. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology. 2001;221(2):380-90.
16-Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology. 2004;233(3):701-8.
17-Wefer A, Hricak H, Vigneron D, Coakley F, Lu Y, Wefer J, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. The Journal of urology. 2000;164(2):400-4.
18-Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging—clinicopathologic study. Radiology. 1999;213(2):473-80.
19-Yuen J, Thng C, Tan P, Khin L, Phee S, Xiao D, et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. The Journal of urology. 2004;171(4):1482-6.
20-Prando A, Kurhanewicz J, Borges AP, Oliveira Jr EM, Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology. 2005;236(3):903-10.
21-Giskeødegård GF, Hansen AF, Bertilsson H, Gonzalez SV, Kristiansen KA, Bruheim P, et al. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia. British journal of cancer. 2015;113(12):1712-9.
22-Chen M, Dang H-D, Wang J-Y, Zhou C, Li S-Y, Wang W-C, et al. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiologica. 2008;49(5):602-10.
23-Gouhar GK, Taha TF, Allam MN. Detection of prostate cancer: Utility of diffusion-weighted MR imaging and 3D MR spectroscopic imaging. The Egyptian Journal of Radiology and Nuclear Medicine. 2010;41(3):429-39.
24-Jagannathan D, Indiran V. Accuracy of Diffusion Weighted Images and MR Spectroscopy in Prostate Lesions–Our Experience with Endorectal Coil on 1.5 T MRI. Journal of clinical and diagnostic research: JCDR. 2017;11(5):TC10.
25-Meier-Schroers M, Kukuk G, Wolter K, Decker G, Fischer S, Marx C, et al. Differentiation of prostatitis and prostate cancer using the Prostate Imaging - Reporting and Data System (PI-RADS). European Journal of Radiology. 2016;85(7):1304-11.
26-Cornel EB, Smits GAHJ, Oosterhof GON, Karthaus HFM, Debruyne FMJ, Schalken JA, et al. Characterization of Human Prostate-Cancer, Benign Prostatic Hyperplasia and Normal Prostate by in-Vitro H-1 and P-31 Magnetic-Resonance Spectroscopy. Journal of Urology. 1993;150(6):2019-24.
27-Kim JK, Kim DY, Lee YH, Sung NK, Chung DS, Kim OD, et al. In vivo differential diagnosis of prostate cancer and benign prostatic hyperplasia: Localized proton magnetic resonance spectroscopy using external-body surface coil. Magnetic resonance imaging. 1998;16(10):1281-8.
28-Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology. 1995;45(3):459-66.
29-García-Segura JM, Sánchez-Chapado M, Ibarburen C, Viaño J, Angulo JC, González J, et al. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. Magnetic resonance imaging. 1999;17(5):755-65.
30-Yue K, Marumoto A, Binesh N, Thomas MA. 2D JPRESS of human prostates using an endorectal receiver coil. Magnetic resonance in medicine. 2002;47(6):1059-64.
31-Zhang XQ, Yu XR, Du ZL, Miao XF, Lu J, Zhou Q. Three-dimensional proton magnetic resonance spectroscopy and diffusion-weighted imaging in the differentiation of incidental prostate carcinoma from benign prostate hyperplasia. Oncology letters. 2018;15(5):6541-6.
32-Zhang TH, Hu CH, Chen JX, Xu ZD, Shen JK. Differentiation Diagnosis of Hypo-Intense T2 Area in Unilateral Peripheral Zone of Prostate Using Magnetic Resonance Spectroscopy (MRS): Prostate Carcinoma versus Prostatitis. Medical science monitor : international medical journal of experimental and clinical research. 2017;23:3837-43.
33-Claus FG, Hricak H, Hattery RR. Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. Radiographics. 2004;24(suppl_1):S167-S80.
34-Carter HB. Diagnosis and staging of prostate cancer. Campbell's urology. 1998;3:2519-37.
35-Ikonen S, Kivisaari L, Tervahartiala P, Vehmas T, Taari K, Rannikko S. Prostatic MR imaging: accuracy in differentiating cancer from other prostatic disorders. Acta radiologica. 2001;42(4):348-54.
36-Hricak H, White S, Vigneron D, Kurhanewicz J, Kosco A, Levin D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils. Radiology. 1994;193(3):703-9.
37-Jager GJ, Severens JL, Thornbury JR, de la Rosette JJ, Ruijs SH, Barentsz JO. Prostate cancer staging: should MR imaging be used?—A decision analytic approach. Radiology. 2000;215(2):445-51.
38-Cookson MS, Fleshner NE, Soloway SM, Fair WR. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. The Journal of urology. 1997;157(2):559-62.
39-Zakian KL, Sircar K, Hricak H, Chen H-N, Shukla-Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234(3):804-14.
40-Garcia-Segura J, Sanchez-Chapado M, Ibarburen C, Viano J, Angulo J, Gonzalez J, et al. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. Magnetic resonance imaging. 1999;17(5):755-65.
Jundishapur Scientific Medical Journal
Volume 17, Issue 4 - Serial Number 115
November and December 2018
Pages 355-365

Files

History

  • Receive Date: 11 September 2018
  • Revise Date: 19 November 2018
  • Accept Date: 19 November 2018

Share

How to cite

Statistics